Kidney Cancer Drugs Market Booming in 2018 and Predicted to Achieve Double Digit CAGR by 2026

Various key drug manufacturers are increasingly gaining regulatory drug approval for the treatment of renal cell carcinoma. These key players are launching novel and superior drug candidates in the market to capture more market share. Growing launch of innovative drugs for the treatment of renal cell carcinoma will fuel the growth of market during the forecast period.

For instance, in April 2018, U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg, injections for intravenous use, as the first immuno-oncology combination therapy for previously untreated patients with intermediate, and poor-risk advanced renal cell carcinoma (RCC). The combination decreased the risk of death by 37 percent compared to Sutent: a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) and the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2399

In December 2017, the U.S. FDA granted regular approval to Exelixis, Inc.’s cabozantinib (Cabometyx) as a first line treatment for patients with advanced renal cell carcinoma (RCC). In 2016, FDA approved Cabometyx for treatment of patients with advanced RCC who received prior anti-angiogenic therapy.

Furthermore, key players are focusing on product development through strategic collaborations and commercial expansion in emerging markets. This could lead to make market more competitive, increase revenue growth of key players, and offer lucrative growth outlook during the forecast period.

Biosimilar development is gaining traction as a promising market opportunity in kidney cancer therapeutics. Several biotech companies launched Avastin biosimilars across several cancer indications in emerging markets such as India, Russia, and Argentina. For instance, in November 2017, Biocon Ltd. launched its biosimilar, bevacizumab, for the treatment of several types of cancer, under the brand name Krabeva in India, in 100 mg/4 ml vials and 400 mg/16 ml vials formulation. Krabeva is indicated as a first-line treatment for patients with metastatic colorectal cancer and used to treat lung, kidney, cervical, ovarian, and brain cancers.

Key players operating in the global kidney cancer drugs market include, Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. and Exelixis, Inc.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2399

Detailed Segmentation:

Global Kidney Cancer Drugs Market, By Therapy:
Targeted Therapy
Immunotherapy
Chemotherapy
Global Kidney Cancer Drugs Market, By Pharmacological Class:
Angiogenesis Inhibitors
mTOR Inhibitors
Cytokines
Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
Global Kidney Cancer Drugs Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.